SCHIZOPHRENIA

This study tested whether a 4-week ketogenic diet (very low carb, high fat) could improve brain function and thinking skills in 71 adults with schizophrenia or bipolar disorder. The idea is that ketones, which the body makes on this diet, may provide better energy to the brain th…

This study tested a remote, personalized program to help 36 adults with schizophrenia take their medication regularly. Participants either received the program or standard care for 12 weeks. The goal was to see if the program was easy to use and helpful, and if it improved sympto…

This study tested a new drug called SEP-363856 to see if it is safe for people with schizophrenia to take over a long period. About 305 adults aged 18 to 65 with schizophrenia took part for up to 57 weeks. The main goal was to track any side effects or serious health issues that …

This study looked at whether people with schizophrenia could safely switch to a new medication called SEP-363856 from their current antipsychotic drugs. About 100 stable patients took the new drug for 8 weeks. Researchers tracked how many stopped treatment due to side effects or …

This study tested a new long-acting injectable form of olanzapine (TV-44749) in 153 people with schizophrenia. The goal was to see if the shot delivers the same amount of medicine into the body as the standard oral tablet. Researchers also checked for side effects. The study last…

This study tested the long-term safety and effectiveness of a drug called MP-214 in 125 people with chronic schizophrenia or elderly patients aged 65-74. The main goal was to see how many participants had side effects. The study is complete, but results are not yet published.

This study looked at the long-term safety of the drug brexpiprazole in teenagers aged 13 to 17 with schizophrenia. Researchers monitored 295 participants for side effects over time. The goal was to see if the drug is safe enough for ongoing maintenance treatment.

This study tested the long-term safety of KarXT, a new medication for schizophrenia, in 566 adults aged 18 to 65. Participants took KarXT twice daily for up to 52 weeks. The main goal was to see how safe and tolerable the drug is over time, with a focus on side effects. This is a…

This study looked at how well Risperidone ISM works in real-world settings for people with schizophrenia who were hospitalized after a relapse. Researchers tracked 275 patients over 56 days to see if their symptoms and daily functioning improved. The goal was to understand the dr…

This study tested whether a gentle brain stimulation technique called tDCS can help people with schizophrenia whose symptoms don't fully improve with medication alone. 141 participants received either real or fake (placebo) stimulation over 5 days. The goal was to see if the real…

This study looked at whether taking a new once-weekly form of the schizophrenia drug brexpiprazole with food changes how the body absorbs it. Fifty-nine adults with stable schizophrenia took the drug once with food and once without, and researchers measured drug levels in their b…

This early-phase study tested a new formulation of risperidone given as a shot every three months in 58 adults with schizophrenia. The goal was to see how the drug moves through the body and if it is safe. Participants were already stable on oral risperidone and received a single…

This study tested whether adding a medication could make targeted cognitive training (TCT) more effective for people with schizophrenia or schizoaffective disorder. 68 adults completed 30 sessions of TCT while taking either the study drug or a placebo. The goal was to see if the …

This study tested a new medicine called LB-102 in 359 adults with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and confusion better than a placebo over 28 days. Researchers measured changes using standard symptom scales and also checked safe…

This study tested whether a new drug, VHX-896, works similarly in the body to the approved medication iloperidone. 26 adults with stable schizophrenia or bipolar I disorder took both drugs to compare their effects and safety. The goal was to see if VHX-896 could be a future treat…

This study compared a new generic version of paliperidone palmitate injection to the standard brand-name drug in 256 Chinese adults with schizophrenia. The goal was to see if the new version reaches similar levels in the blood, meaning it should work just as well. Participants re…

This study looked at the long-term safety of the drug cariprazine in 310 children and teens with schizophrenia, bipolar I disorder, or autism spectrum disorder. Over 52 weeks, researchers monitored side effects, movement changes, and lab results. The goal was to understand the ri…

This study tested two smartphone-based programs to help people with schizophrenia manage their mental health. 299 adults who owned a smartphone and were already receiving care at participating clinics took part. The programs aimed to reduce symptoms like depression, anxiety, and …

This study tested whether a mindfulness-based psychoeducation program could help people with schizophrenia improve their mindfulness and stick to their medication. Forty stable outpatients were randomly assigned to either the mindfulness program or usual care. Results showed that…

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. About 75 adults who completed a prior study took the new drug for up to 25 weeks. Researchers tracked side effects to see if the d…

This study tested whether delivering mental health services by video (telehealth) helps young people with psychotic disorders stay engaged in care and avoid hospital stays better than standard in-person clinic visits. 74 people aged 16-35 with early psychosis took part. The goal …

This study compared two ways to help people with serious mental illness quit smoking: a smartphone app designed for them (Quit on the Go) versus standard care. 343 participants were followed for 6 months to see who stopped smoking, verified by a breath test. The goal was to find …

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 adults with schizophrenia. Participants had already completed an earlier study and continued taking MP-214 to see how well it was tolerated over time. The main focus was on tracking any side effe…

This study tested a joint crisis plan, called the SOS plan, to see if it could reduce hospitalizations in people with schizophrenia or schizoaffective disorder. The plan involves the patient, their healthcare team, and family members working together to create a personalized plan…

This early-stage study tested the safety of the medication brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia. Researchers monitored side effects, vital signs, and how the drug moved through the body over 17 days. The goal was to see if the drug is safe enough for lar…

This study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking one or more antipsychotic medications. The main goal was to track any side effects over time. The study did not aim to cure…

This study tested a new long-acting injectable form of olanzapine (TV-44749) in 675 adults with schizophrenia. The goal was to see if it controls symptoms better than a placebo over 8 weeks, with a focus on safety and tolerability. Participants received the injection weekly or mo…

This study tested whether a new version of the schizophrenia medication brexpiprazole gets into the bloodstream the same way as the already-approved version. It involved 36 healthy adults who took single doses of each drug. The goal was to see if the two versions are bioequivalen…

This study tested whether a higher dose of a long-acting injectable antipsychotic medication works better than the standard dose for people with schizophrenia or schizoaffective disorder. It involved 160 participants whose symptoms weren't well-controlled on their current medicat…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia in people experiencing a sudden worsening of their condition. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control. The main goal was to me…

This study tested whether an experimental drug called TAK-063 can reduce symptoms of schizophrenia during a sudden worsening (acute exacerbation). 164 adults with schizophrenia took either TAK-063 or a placebo daily for 6 weeks. The main goal was to see if the drug improved score…

This study tested an experimental drug called MP-214 in 34 adults with schizophrenia. Participants took one of three doses daily for 14 days to see if it was safe and could help control symptoms. The goal was to measure side effects, drug levels in the blood, and any improvement …

This study looked at how safe and how well the body handles a drug called lumateperone in teenagers aged 13 to 17 with schizophrenia or schizoaffective disorder. 26 teens took the drug by mouth, and researchers measured its levels in the blood and checked for side effects. The go…

This study looked at whether a second course of a smartphone app could help ease negative symptoms of schizophrenia, like lack of motivation and pleasure. 73 adults who had already used the app in a previous study used it again for 16 weeks alongside their usual medication. The g…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Participants were stable on their current treatment and in …

This study looked at whether virtual reality training or physical activity works better to improve physical function, thinking skills, and quality of life in people with schizophrenia. 45 adults with schizophrenia took part. The goal is to find new ways to help manage symptoms an…

This study tested whether a 4-week virtual reality (VR) training program could improve thinking skills and daily functioning in 62 adults with stable mood disorders (like depression or bipolar disorder) or psychosis spectrum disorders (like schizophrenia). Participants used VR to…

This study tested a new drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. The goal was to see if the drug could reduce symptoms like hallucinations and delusions better than a placebo over 6 weeks. The trial compared ITI-007 to b…

This early-stage study tested an experimental drug called TAK-063 in 77 people—some with stable schizophrenia and some healthy Japanese volunteers. The main goal was to see if the drug is safe and tolerable when taken daily for a week. Researchers monitored side effects, lab test…

This study tested a group-based cognitive training program for people with schizophrenia. The goal was to see if it improves daily functioning and is worth the cost compared to usual care. 218 patients with less than 10 years of illness took part. The training focused on practica…

This study tested whether luteolin, a natural substance found in celery and chamomile tea, can improve symptoms of schizophrenia. 85 adults with schizophrenia or schizoaffective disorder took either luteolin or a placebo. The goal was to see if luteolin reduces overall symptoms, …

This study tested a new medicine called CPL500036 in 189 people with schizophrenia who were having a sudden worsening of symptoms. The goal was to see if the drug could reduce symptoms like hallucinations or delusions over 28 days compared to a placebo. Researchers measured chang…

This study tested whether two types of gentle electrical brain stimulation (tDCS and tRNS) could improve thinking and memory in people with schizophrenia. 36 adults completed thinking games and questionnaires after each type of stimulation. The goal was to see if these safe, non-…

This study tested whether a non-invasive brain stimulation technique called rTMS, guided by detailed MRI scans, could reduce severe hallucinations in people with schizophrenia whose symptoms did not improve with medication. 85 participants received either real or fake rTMS to see…

This early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Participants took multiple doses and were closely monitored f…

This study tested whether patients with schizophrenia or schizoaffective disorder could improve their awareness of their illness by watching a video of themselves recorded during an acute episode. 60 patients were randomly assigned to either watch the video or receive standard ca…

This study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who did not respond well to treatment alone. Over 400 participants took either valbenazine or a placebo for 10 weeks. The main goal was to see if valben…

This study tested an experimental drug called MP-214 in 512 people with schizophrenia who were having a sudden worsening of symptoms. The goal was to see if the drug reduces symptoms like hallucinations and delusions better than a placebo over 6 weeks. Researchers measured change…

This study looked at how well valbenazine works for tardive dyskinesia, a condition causing uncontrollable movements often linked to psychiatric medications. Fifty-nine adults with schizophrenia, bipolar disorder, or major depression took valbenazine for up to 24 weeks. Researche…

This study tested whether a daily tablet called iclepertin can help improve memory and thinking in adults with schizophrenia. About 620 participants took either the drug or a placebo for 26 weeks while continuing their usual schizophrenia medications. Researchers measured changes…

This study looked at whether adding behavioral skills training to standard job support helps people with schizophrenia stay employed longer. 107 participants who were taking risperidone or olanzapine took part. The main goal was to see how many weeks they could work.

This study tested a noninvasive brain stimulation technique called transcranial random noise stimulation to see if it could reduce cravings in 225 adults with substance use disorder plus another mental health condition like ADHD, bipolar disorder, or schizophrenia. Participants r…

This study tested a daily tablet called iclepertin to see if it could improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medications. Resear…

This study tested whether adding KarXT (a combination of two medicines) to standard antipsychotic treatment helps reduce schizophrenia symptoms that were not well controlled. About 400 adults with schizophrenia took either KarXT or a placebo for 6 weeks. The main goal was to see …

This study tested whether adding structured supportive psychotherapy to the antipsychotic risperidone helps improve cognitive function and reduce inflammation in people with schizophrenia. Forty-six men with early-stage schizophrenia took part. Half received risperidone plus 12 s…

This study tested whether adding curcumin (the active compound in turmeric) to the standard medication risperidone could improve quality of life and reduce inflammation in people with schizophrenia. Forty-four men took either risperidone alone or risperidone plus curcumin for 8 w…

This study tested a new drug called CVL-231 (Emraclidine) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took either a low dose, a high dose, or a placebo pill daily for 6 weeks. The goal was to see if the drug reduces symp…

This study tested a group therapy program called Social Cognition Interaction Training (SCIT) in 51 adults with schizophrenia or schizoaffective disorder. The goal was to see if practicing social thinking skills could improve how they understand emotions and interact with others.…

This study tested whether a daily medicine called iclepertin can improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia treatment. Researchers m…

This study tested an experimental drug called AVP-786 in 145 adults with schizophrenia who still had troubling symptoms despite taking their usual antipsychotic medication. The goal was to see if adding AVP-786 could reduce negative symptoms like lack of motivation and social wit…

This study tested whether adding the drug memantine to a computer-based cognitive training program helps improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 62 adults took part in a 13-week trial where some received memantine and others a…

This study tested two smartphone-based treatments (prescription digital therapeutics) in 464 adults and teens with schizophrenia who were already taking antipsychotic medication. The goal was to see if these digital programs could help with negative symptoms like lack of motivati…

This study tested a special type of brain stimulation called theta-burst TMS in 76 adults with schizophrenia. The goal was to see if it could safely reduce negative symptoms (like lack of motivation) and improve thinking skills such as memory and emotion recognition. Participants…

This study tested a light-based treatment called photoneuromodulation to help with the negative symptoms of schizophrenia, such as lack of motivation or social withdrawal. Thirty adults who had not responded to other treatments received either real or fake (sham) light sessions, …

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo. Participants took different doses of the drug or a placebo for 6 we…

This study tested a new medication called CVL-231 (Emraclidine) in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took either a low dose, a high dose, or a placebo pill daily for 6 weeks. The main goal was to see if the drug r…

This study tested a new drug called KarXT in 202 Chinese adults hospitalized with schizophrenia. For 5 weeks, some received KarXT and others a placebo to see if the drug reduces symptoms like hallucinations and social withdrawal. After that, everyone could take KarXT for 12 more …

This study looked at how a new drug called MP-214 works in 38 adults with schizophrenia. Researchers measured safety, how the drug moves through the body, and whether it helps control symptoms over 12 weeks. The goal was to find the right dose and check for side effects.

This study tested whether a new drug called ITI-007 can reduce schizophrenia symptoms better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took either the drug or a placebo for 28 days. The main goal was to see if their symptom…

This study looked at whether aerobic exercise or computer-based cognitive training better helps thinking skills in people with schizophrenia. Fifty-eight adults with schizophrenia took part. Researchers measured changes in memory, attention, and problem-solving using standard tes…

This study tested a program called Metacognitive Training (MCT) in 18 adults with schizophrenia, major depression, or bipolar disorder in Taiwan. Over four weeks, participants attended eight group sessions designed to help them recognize and adjust unhelpful thinking patterns. Th…

This early-phase study tested the safety and tolerability of a new drug called MK-8189 (elpipodect) in 63 adults with schizophrenia, including both younger and elderly participants. The goal was to find safe dosing schedules and see how the drug moves through the body. No claims …

This study tested an investigational medication called BXCL501 for calming agitation episodes in people with bipolar disorder, schizophrenia, or related conditions. 452 adults took either the drug or a placebo, and researchers measured changes in agitation levels and safety. The …

This study tested whether taking part in art activities (like painting, music, or dance) can improve mental well-being and reduce symptoms of anxiety and depression. 382 people with mental health issues were randomly assigned to either an art program or a waitlist. The researcher…

This study tested whether virtual reality could help people with schizophrenia improve their social skills and daily functioning. Thirty-seven participants with stable schizophrenia completed 12 weekly VR sessions that simulated real-life social situations. Researchers measured w…

This study used advanced brain scans (MRI and MEG) to compare the brains of over 3,000 people with schizophrenia and healthy volunteers. The goal was to find differences in brain structure, chemistry, and activity that could help explain schizophrenia. Participants did not receiv…

This completed study used PET scans to watch brain activity while people performed thinking tasks. It included healthy volunteers and people with schizophrenia or Parkinson's disease. The goal was to learn how the frontal lobe works during thinking and how certain drugs might aff…

This study looked at what happens when people with schizophrenia or bipolar disorder take Igalmi repeatedly for agitation over 7 days, and then stop. Researchers wanted to see if the drug becomes less effective (tolerance) or causes withdrawal symptoms. 29 adults participated in …

This study looked at whether a type of talk therapy called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) works for veterans who also have serious mental illnesses like schizophrenia or bipolar disorder. 47 veterans took part to see if the therapy was acceptable and helpf…

This study looked at how two schizophrenia medicines, risperidone and aripiprazole, affect the energy-producing parts of cells (mitochondria) in 60 patients. The goal was to understand if these drugs cause cell energy problems that might lead to side effects. It was not designed …

This study looked at whether cannabis or a similar drug (dronabinol) can fix brain reward problems in people with schizophrenia who also use cannabis. Researchers measured brain activity using fMRI scans in 263 participants. The goal was to understand if cannabis might act as a f…

This study tested whether a smartphone app could passively track activity, sociability, and sleep in 87 veterans with serious mental illnesses like schizophrenia and bipolar disorder. The goal was to see if this data could help detect early warning signs of relapse. The study foc…

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) causes heart rhythm changes in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug's effect…

This study tested whether sending text message reminders helps young people (ages 14-35) with psychosis attend their first appointment at an early psychosis program after being seen in the emergency room. Researchers enrolled 186 participants and tracked whether they showed up fo…

This pilot study tested a new automated phone system called 'My Coach Connect' for people with chronic mental illness. Participants called the system twice a week to share how they were doing, and their providers could listen to the recordings. The goal was to see if this tool co…

This study tested whether customizing cognitive training based on a person's early auditory processing ability improves thinking and daily functioning in people with schizophrenia or schizoaffective disorder. 194 adults from community mental health centers were grouped by their a…

This study checked the mouth and teeth of 110 adults with schizophrenia in France. Researchers did a dental exam, took a blood sample to check vitamin C levels, and asked about dental care and eating habits. The goal was to understand their oral health and find ways to help.

This study tested a new artificial intelligence tool called CBTpro that helps therapists improve their skills in cognitive behavioral therapy for psychosis (CBTp). Over 600 adults with conditions like schizophrenia, bipolar disorder, or severe depression took part. The goal was t…

This study looked at how young adults aged 18-30 with early psychosis process information from their surroundings, compared to those without a psychiatric diagnosis. Participants completed computer-based tasks and cognitive training to measure changes in attention and decision-ma…

This study looked at how a single dose of an experimental drug for schizophrenia, SEP-380135, is processed in the body when taken with another drug that affects a key liver enzyme. Twelve healthy adults participated to measure drug levels and safety. The goal was to gather inform…

This study tested a telehealth program called CRAFT-EP for families of people with early psychosis who also use alcohol or cannabis. 65 family members participated to see if the program improved their wellbeing, including depression and anxiety. The goal was to learn if this appr…

This early-phase study tested an experimental drug called MK-8189 in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to see if the drug is safe and how the body processes it. This study does not aim to treat or cure schizophrenia, but to ga…

This study looked at how teenagers with autism or schizophrenia understand emotions, intentions, and social situations compared to healthy teens. Researchers used brain wave tests and cognitive tasks to find similarities and differences. The goal was to learn more about these con…

This study looked at how young people (ages 15-35) who have a parent or sibling with schizophrenia process social cues like facial expressions. Researchers used brain scans and emotion recognition tests to understand their social thinking patterns. They also tested whether a comp…

This study looked at how people with schizophrenia organize memories of everyday events. About 80 participants, including patients and healthy volunteers, took a 1-hour walk in Strasbourg while wearing an automatic camera. Later, they were asked to put photos from the walk in ord…

This study used PET scans to look at dopamine and blood flow in the brains of 502 people, including healthy volunteers and those with Parkinson's disease or schizophrenia. The goal was to understand how dopamine problems affect these conditions. No treatment was given; it was pur…

This study tested whether a program combining education about schizophrenia with motivational interviewing could help patients learn more about their condition and feel more hopeful. 44 adults with schizophrenia who were not in an acute phase took part. The results showed that th…

This study looked at how people aged 15-45 with early psychosis process information about their surroundings, compared to healthy young adults. Participants completed computer tasks while their brain activity was measured using EEG and MRI. The goal was to understand brain functi…

This study looked at how a non-invasive brain stimulation technique called TMS changes brain activity in people with schizophrenia. Ten participants received both real and fake TMS sessions, and researchers measured brain connectivity and electrical signals before and after. The …

This study followed 51 people with schizophrenia who were already stable on long-acting injectable antipsychotics for 48 weeks. Researchers wanted to see how often psychotic symptoms return when patients take their medication as prescribed. They also checked blood levels of the d…

This study tested two types of brain stimulation (TMS) in 90 people who smoke, half with schizophrenia and half without. The goal was to see if TMS could change brain connections linked to nicotine use and reduce cravings. Participants had their cravings and thinking skills measu…

This study looked at how the brain creates the feeling of being in control of one's own actions. Researchers compared healthy volunteers with people who have schizophrenia or bipolar disorder, especially those who feel their actions are controlled by an outside force. The goal wa…

This study looked at how a natural brain chemical called kynurenic acid (KYNA) affects thinking and memory in people with schizophrenia. Researchers gave participants tryptophan (a common amino acid) to raise KYNA levels, then tested whether the supplement N-acetylcysteine (NAC) …

This study looked at 100 veterans with mental health conditions like schizophrenia, PTSD, anxiety, or mood disorders. The goal was to see if a simple brain wave test (called mismatch negativity) could help choose the best thinking skills training for each person. Researchers meas…

This study looked at how dopamine receptors in the brain work in people with schizophrenia compared to healthy volunteers. Researchers used special PET and MRI scans to measure two types of dopamine receptors. The goal was to better understand what causes schizophrenia, which cou…

This study tested a program called Illness Management and Recovery (IMR) for adults with schizophrenia or bipolar disorder. The goal was to see if the program helps improve daily functioning compared to usual care. 198 people from two community mental health centers in Denmark to…

This study looked at 168 pregnant or breastfeeding women with serious mental health conditions like schizophrenia or mania who were taking long-acting injectable antipsychotics. Researchers measured drug levels in the mother's blood, breastmilk, and the baby's blood to understand…

This study tested a new questionnaire to understand how people with schizophrenia feel about their oral health. Researchers asked 59 patients to fill out surveys about their teeth, gums, and quality of life. The goal is to create a reliable tool that can help doctors design bette…

This study looked at whether a digital training platform helps clinicians use a mobile health app called FOCUS to support people with serious mental illness like schizophrenia, bipolar disorder, or major depression. About 191 adults used the app and received coaching from trained…

This completed study from the National Institute of Mental Health looked at nearly 5,000 people with schizophrenia or related disorders, along with their siblings. The goal was to find genes linked to the illness and see how they affect brain function. By understanding these conn…

This study looked at how low and high frequency magnetic brain stimulation (rTMS) changes brain waves in 30 healthy adults. Participants received both 1 Hz and 20 Hz stimulation in separate sessions, and their brain activity was measured with EEG before and after. The goal was to…

This study looked at whether a program called NAVIGATE helps youth (ages 14-35) having their first episode of psychosis get better coordinated care. Researchers worked with 100 participants across Ontario to see if the program reduces hospital stays and ER visits. The goal was to…

This study tested a training program called Collaborative Decision Skills Training (CDST) to help veterans with serious mental illness, like schizophrenia, work more closely with their doctors in making treatment decisions. The program involved 8 weekly group sessions, and resear…

This study tested whether a support group led by trained peers (people who also have schizophrenia) can help patients learn more about their illness and improve their symptoms and daily functioning. Over 300 adults with schizophrenia took part and were followed for two years. The…

This study tested whether special visual exercises could improve how people with schizophrenia see and process visual information. About 79 adults with schizophrenia or schizoaffective disorder took part. The training focused on two visual skills often affected by the condition: …

This study looked at whether a learning technique called retrieval practice (testing yourself on material) works for people with schizophrenia. 40 participants, including patients and healthy volunteers, studied word pairs and were tested two days later. The goal was to see if te…

This study looked at 648 people with schizophrenia to understand the illness itself versus the effects of medication. Participants stayed in the hospital and temporarily stopped their antipsychotic drugs under close supervision. Researchers used brain scans and tests to see how t…

This study looked at how people aged 15-45 with early psychosis process information about their environment, compared to those without a psychiatric diagnosis. Researchers tested two types of cognitive training and measured changes in brain activity and task performance using com…

This study looked at whether family members or caregivers can help measure agitation in people with bipolar disorder or schizophrenia. 33 adults took a single dose of an experimental medicine, and researchers compared ratings from doctors, patients, and their family members. The …

This study tested a new training program called iTEST for 69 adults with schizophrenia or schizoaffective disorder. The program uses daily mobile tasks, like guessing emotions from faces or remembering words, to help people improve how accurately they judge their own performance.…